ALSPW Spineway SAS

Spineway : Strengthening corporate governance appointment of two new board members

Spineway : Strengthening corporate governance appointment of two new board members



Strengthening corporate governance

Appointment of two new board members



An Ordinary and Extraordinary General Meeting of Spineway’s shareholders met pursuant to a second notice of meeting at 10:30 a.m. on 24 July 2019 at the company’s registered office. The number of shares held by the 22 shareholders present or represented amounted to 19 610 640, representing 21 335 325 votes, which meant a turnout of 14.19%. All of the ordinary resolutions were adopted. The extraordinary resolutions could not be put to a vote in the absence of a quorum.

During this General Meeting, the shareholders approved the company’s annual accounts and the appointment of Mr. Bernard Kubbinga and Mr. Roberto Albisetti as board members to help strengthen the Group’s positions in Latin America.

These new board members will be able to share their experience and knowledge with Spineway’s Board of Directors following the capital investment in INTEGRAL MEDICAL SOLUTIONS (IMS)1 with respect to the follow-up and management of its establishment in Latin America, as well as its future development in Africa.

Mr. Bernard Kubbinga

Born in 1957 in La Paz (Bolivia), Mr. Kubbinga is a graduate of EHL in Lausanne (Switzerland). He speaks six languages and has acquired significant international experience thanks to his career path. After many years with the Compagnie Internationale des Wagons-Lits et du Tourisme in Paris, where he was in charge of financial auditing, he went abroad and became the financial officer for the Andes region. He continued his career on the African continent where he created a distribution network for goods from West Germany, Indonesia, China and South Africa. He now lives in Dominican Republic where he manages his distribution network and is on the board of several compagnies.

Mr. Roberto Albisetti

Born in 1956 in Genoa (Italy), Mr. Albisetti is a banker, business consultant and university professor. He has had extensive professional experience abroad (USA, Europe, Mexico, Colombia and Moldavia, among other countries) acquired in the various fields of finance, industry, teaching, natural resources and healthcare. He assisted many companies with their strategic planning, structuring investments, mergers and acquisitions, as well as investment capital. He was a professor of finance and entrepreneurship at SDA Bocconi Business School in Milan, the University of Genoa and several other universities in Colombia and in Mexico. He has also been Vice President of the Italian export credit agency (SACE), adviser to the Italian member of the World Bank’s Board of Directors and member of the board of the Italian group IRI-Finmeccanica.

The fields of expertise as well as the diverse know-how of these two board members will be major assets to Spineway’s development.

Next communication: 2019 half-year results – 29 October 2019

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW              

Contacts:

Spineway



Shareholder-services line

Available Tuesday through Thursday

(10 a.m. – 12 p.m.)

+33 (0)811 045 555



 




Aelium



Finance et Communication



Investor relations

Solène Kennis








1 See Spineway’s press release dated 16 May 2019.



Attachment

EN
25/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch